Literature DB >> 24570904

Prevention of chronic HBV infection induced hepatocellular carcinoma development by using antiplatelet drugs.

Kuan-Han Lee1, Chin-Jen Wu2, Clay C C Wang3, Jui-Hsiang Hung4.   

Abstract

Entities:  

Year:  2012        PMID： 24570904      PMCID： PMC3924632          DOI： 10.3978/j.issn.2304-3881.2012.10.09

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  12 in total

1.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

Review 2.  Regulation of platelet functions by P2 receptors.

Authors:  Christian Gachet
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

Review 3.  Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Liver Int       Date:  2005-08       Impact factor: 5.828

4.  Platelets mediate cytotoxic T lymphocyte-induced liver damage.

Authors:  Matteo Iannacone; Giovanni Sitia; Masanori Isogawa; Patrizia Marchese; Maria G Castro; Pedro R Lowenstein; Francis V Chisari; Zaverio M Ruggeri; Luca G Guidotti
Journal:  Nat Med       Date:  2005-10-30       Impact factor: 53.440

5.  Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum.

Authors:  S Sherlock; R A Fox; S P Niazi; P J Scheuer
Journal:  Lancet       Date:  1970-06-13       Impact factor: 79.321

6.  Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.

Authors:  Giovanni Sitia; Roberto Aiolfi; Pietro Di Lucia; Marta Mainetti; Amleto Fiocchi; Francesca Mingozzi; Antonio Esposito; Zaverio M Ruggeri; Francis V Chisari; Matteo Iannacone; Luca G Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

7.  Immune effectors required for hepatitis B virus clearance.

Authors:  Priscilla L Yang; Alana Althage; Josan Chung; Holly Maier; Stefan Wieland; Masanori Isogawa; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 8.  Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.

Authors:  Marco Cattaneo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-23       Impact factor: 8.311

9.  Hepatitis B X-gene expression in hepatocellular carcinoma.

Authors:  I D Diamantis; C E McGandy; T J Chen; Y F Liaw; F Gudat; L Bianchi
Journal:  J Hepatol       Date:  1992-07       Impact factor: 25.083

10.  Involvement of platelets in tumour angiogenesis?

Authors:  H M Pinedo; H M Verheul; R J D'Amato; J Folkman
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321
View more
  3 in total

1.  Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation.

Authors:  Juan Li; Junru Liu; Beihui Huang; Dong Zheng; Mei Chen; Zhenhai Zhou; Duorong Xu; Waiyi Zou
Journal:  Tumour Biol       Date:  2013-02-23

2.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

3.  Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.

Authors:  Feng Xia; Li-Li Wu; Wan-Yee Lau; Hong-Bo Huan; Xu-Dong Wen; Kuan-Sheng Ma; Xiao-Wu Li; Ping Bie
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.